Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Wang Welcomes the FDA Approval of Brexucabtagene Autoleucel in MCL

July 30th 2020

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL Models

July 24th 2020

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Dr. Wang on the FDA Approval of Brexucabtagene Autoleucel in MCL

July 24th 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory MCL

July 24th 2020

The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Dr. Leslie on Current Treatment Options for Relapsed/Refractory MCL

July 23rd 2020

Lori A. Leslie, MD, discusses current treatment options for patients with relapsed/refractory mantle cell lymphoma.

Calling Attention to Treatment Considerations in MCL

July 22nd 2020

Lori A. Leslie, MD, discusses the current treatment landscape in mantle cell lymphoma, factors to consider when selecting between BTK inhibitors, and other treatment options on the horizon.

Dr. Davids on the Potential Utility of Frontline Ibrutinib/Umbralisib in CLL and MCL

July 22nd 2020

Matthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib and umbralisib into the frontline setting of chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL

July 21st 2020

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Dr. Leslie on the Role of BTK Inhibitors in Relapsed/Refractory MCL

July 20th 2020

Lori A. Leslie, MD, discusses the role of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Roué on ​the Next Steps ​With TG-1701 in MCL

July 20th 2020

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.

Dr. Davids on the Potential Utility of Ibrutinib/Umbralisib in MCL and CLL

July 15th 2020

Matthew S. Davids, MD, MMSc, discusses the potential utility of ibrutinib in combination with umbralisib in patients with mantle cell lymphoma or relapsed/refractory chronic lymphocytic leukemia.

Dr. Leslie on the Current Frontline Treatment Landscape in MCL

July 14th 2020

Lori A. Leslie, MD, discusses the current frontline treatment landscape in mantle cell lymphoma.

Dr. Martin on the Frontline Treatment Landscape of MCL

July 13th 2020

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Dr. Leslie on Remaining Questions to Address in MCL

July 11th 2020

Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.

Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models

July 9th 2020

Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Dr. Leslie on the Benefits With Zanubrutinib in MCL

July 9th 2020

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Dr. Davids on Updated Data With Ibrutinib/Umbralisib in R/R CLL and MCL

July 8th 2020

Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Ruan on Unanswered Questions Regarding Treatment Decisions in MCL

July 7th 2020

Jia Ruan, MD, PhD, discusses some of the unanswered questions regarding optimizing treatment selection in patients with mantle cell lymphoma.

NEXT PAGE
PREVIOUS PAGE